Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
المؤلفون المشاركون
Tang, Lydia
Kottilil, Shyam
Kamat, M.
Shukla, A.
Vora, M.
Shah, S.
Kalal, Chetan Ramesh
المصدر
Interdisciplinary Perspectives on Infectious Diseases
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-10-01
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Background.
Chronic hepatitis C infection is a major cause for liver failure and liver cancer and can be treated with highly effective all oral directly acting antiviral (DAA) drugs.
Generic versions of these DAAs are available in India.
Method.
This was an open-label, single-center, prospective, nonrandomized observational study for the comparative safety and efficacy of generic versus brand name sofosbuvir with ribavirin therapy for chronic hepatitis C infection (all genotypes).
Between December 2014 and December 2015, 66 patients received either generic sofosbuvir (400mg) or brand name SOLVALDI (400mg) with weight based ribavirin for 24 weeks in a single multispecialty hospital in Mumbai.
Monitoring viral loads and safety labs was performed as per national guidelines.
Results.
Sustained virologic response was 72.4% versus 75.7% (p=0.78) among patients treated with generics and SOVALDI, respectively.
At 4 weeks on-treatment, approximately 90% of patients from both groups had undetectable or below the lower limit of quantification.
Change in hemoglobin was comparable in both groups (p=0.26).
Conclusion.
Generic versions of sofosbuvir reported in this study are safe and efficacious to treat hepatitis C.
However, bioequivalency studies of all generic DAAs need to be performed before wider use of such drugs for the treatment of hepatitis C.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Tang, Lydia& Kamat, M.& Shukla, A.& Vora, M.& Kalal, Chetan Ramesh& Kottilil, Shyam…[et al.]. 2018. Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C. Interdisciplinary Perspectives on Infectious Diseases،Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1175877
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Tang, Lydia…[et al.]. Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C. Interdisciplinary Perspectives on Infectious Diseases No. 2018 (2018), pp.1-9.
https://search.emarefa.net/detail/BIM-1175877
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Tang, Lydia& Kamat, M.& Shukla, A.& Vora, M.& Kalal, Chetan Ramesh& Kottilil, Shyam…[et al.]. Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C. Interdisciplinary Perspectives on Infectious Diseases. 2018. Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1175877
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1175877
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر